Day One Biopharmaceuticals Stock Price

-0.15 (-1.01%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 425,354
Bid Price 10.00
Ask Price 19.00
News -
Day High 15.61


52 Week Range


Day Low 14.28
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Day One Biopharmaceuticals Inc DAWN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.15 -1.01% 14.63 20:00:00
Open Price Low Price High Price Close Price Prev Close
15.03 14.28 15.61 14.63 14.78
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,445 425,354 $ 14.94 $ 6,356,161 - 13.45 - 28.699
Last Trade Time Type Quantity Stock Price Currency
16:01:01 formt 208 $ 14.63 USD


Draw Mode:

Day One Biopharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 906.02M 61.93M 24.58M $ - $ - -0.54 -2.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -2.22M 8.40%

more financials information »

Day One Biopharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DAWN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.0015.6113.4514.53185,1270.634.5%
1 Month15.9017.8313.4515.26206,960-1.27-7.99%
3 Months23.4426.6213.4517.41226,944-8.81-37.59%
6 Months21.4828.69913.4519.88157,663-6.85-31.89%
1 Year25.0028.69913.4520.37160,615-10.37-41.48%
3 Years25.0028.69913.4520.37160,615-10.37-41.48%
5 Years25.0028.69913.4520.37160,615-10.37-41.48%

Day One Biopharmaceuticals Description

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Your Recent History
Day One Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.